CELC · Celcuity Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Celcuity Inc. launched ReftraPIC on September 30th; 78% of its top 36 accounts ordered, and 91% of U.S. commercial and Medicare lives are covered. No third-quarter product revenue was recognized; cash, cash equivalents, and short-term investments reached $642.7 million.
Celcuity launched REVTORPYK after FDA approval for adults with HR+/HER2- ABC without a PIK3CA mutation, but recognized no product revenue through September 30, 2026; its nine-month net loss was $205.0 million.
Celcuity Inc. launched REVTORPYK on September 30, 2026, with 91% of U.S. commercial and Medicare lives covered; third-quarter net loss was $73.3 million, and no product revenue was recognized.
Celcuity Inc. appointed David W. Gryska to its expanded nine-member Board effective October 1, 2026, and to its Audit and Compensation Committees, with a $70,000 annual cash retainer, $100,000 annual equity award, and 893 restricted stock units.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. The REVTORPYK launch showed broad account uptake and payer coverage, while positive mutant-cohort data supported an sNDA and clinical results were reported in breast and prostate cancer. However, Celcuity recognized no product revenue in the quarter, its net loss and operating cash burn increased, operating expenses rose, a $50.0 million milestone was paid to Pfizer, and temporary J-code reimbursement friction remains for some accounts.
- + The REVTORPYK launch reached 78% of the top 36 strategic accounts, representing ~50% of the addressable patient population.
- + REVTORPYK achieved broad payer coverage, with 91% of U.S. commercial and Medicare lives in covered health plans.
- + In PIK3CA mutant patients without liver metastases, median PFS was 21.5 months for the gedatolisib triplet and 11.5 months for the doublet versus 9.1 months for alpelisib plus fulvestrant.
- + Celcuity submitted an sNDA for the PIK3CA mutant indication and plans additional global regulatory submissions.
- + In mCRPC patients previously exposed to abiraterone, median rPFS was 15.7 months and the six-month rPFS rate was 82.2%.
- + Current cash, cash equivalents and investments are expected to finance operations through 2029.
- − Third-quarter net loss widened to $73.3 million, or $1.33 per share, from $43.8 million, or $0.92 per share.
- − No product revenue was recognized during the third quarter because no product was delivered until after quarter-end.
- − Total operating expenses increased to $77.3 million from $42.8 million, while R&D expenses increased to $37.5 million from $30.4 million.
- − SG&A expenses increased by $27.4 million to $39.8 million, primarily because of commercialization staffing and infrastructure.
- − Net cash used in operating activities increased to $66.2 million from $44.8 million, and Celcuity paid a $50.0 million milestone to Pfizer.
- − The temporary J-code creates reimbursement friction for some accounts until it becomes active on April 1.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and short-term investments | $642.7M | the end of the third quarter of 2026 | — |
|
|
|||
| Health care providers who attended REVTORPYK educational programs | 1,100 | as of November 5, 2026 | — |
| Non-GAAP adjusted net loss non-GAAP | -$172.35M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP adjusted net loss per share non-GAAP | $1.21 | third quarter of 2026 | — |
| Non-GAAP adjusted net loss per share - basic and diluted non-GAAP | -$3.14 | Nine Months Ended September 30, 2026 | — |
| Sites directly engaged with Celcuity oncology sales specialists | 3,400 | as of November 5, 2026 | — |
| Top 36 strategic accounts that have ordered REVTORPYK | 78% | as of November 5, 2026 | — |
| U.S. commercial and Medicare lives in health plans that cover REVTORPYK | 91% | as of November 5, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CELC
this stock
Celcuity Inc.
|
$2.73B | -44.3% | — | — | 21.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CELC | -13.6% | -9.7% | -58.2% | -19.6% | -44.3% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -9.7% | -4.1% | -54.7% | -16.2% | -51.3% |